SCHEMBL48728

SCHEMBL48728

O[C@@H]1CNC[C@H]1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29033484 1.00
SCHEMBL357919 1.00
SCHEMBL9885441 1.00
SCHEMBL48795 1.00
SCHEMBL978384 1.00
Hydrochloric Acid SCHEMBL743531 0.96
Hydrochloric Acid SCHEMBL1265950 0.96
Hydrochloric Acid SCHEMBL742834 0.96
Hydrochloric Acid SCHEMBL6034020 0.96
Hydrochloric Acid SCHEMBL48034 0.96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113493628-A Quantum dot ink and preparation method of quantum dot film TCL科技集团股份有限公司 2021-10-12 CN claimed
CN-113122053-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 CN claimed
WO-2026087651-A1 CYCLOPROPANE-ARYL COMPOUNDS FOR THE TREATMENT OF CANCER SANOFI (FR) 2026-04-30 WO disclosed
US-12570645-B2 Uses of p53 x-ray co-crystal structures PMV PHARMACEUTICALS, INC. (US) 2026-03-10 US disclosed
US-20260027097-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-01-29 US disclosed
US-20250319063-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. 2025-10-16 US disclosed
US-12421211-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2025-09-23 US disclosed
US-12419880-B2 Companion diagnostic tool for mutant p53 reactivating compounds PMV PHARMACEUTICALS, INC. (US) 2025-09-23 US disclosed
US-20250250226-A1 IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF NITTO DENKO CORP (JP) 2025-08-07 US disclosed
US-20250179059-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-06-05 US disclosed
US-20250177349-A1 ARYL ALKYNAMIDE DERIVATIVES Astellas Engineered Small Molecules US, Incorporated 2025-06-05 US disclosed
US-20020042409-A1 Thiophene derivatives useful as anticancer agents PFIZER PRODUCTS INC. 2002-04-11 US disclosed
US-20020028810-A1 Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals HOOVER DENNIS J (US) 2002-03-07 US disclosed
WO-2001040217-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS PFIZER PRODUCTS INC. (US) 2001-06-07 WO disclosed
EP-1070065-A1 AZABICYCLIC 5HT1 RECEPTOR LIGANDS Pfizer Products Inc. (US) 2001-01-24 EP disclosed
WO-1999052907-A1 AZABICYCLIC 5HT1 RECEPTOR LIGANDS PFIZER PRODUCTS INC. (US) 1999-10-21 WO disclosed
EP-0832065-A1 SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS PFIZER INC. (US) 1998-04-01 EP disclosed
WO-1996039385-A1 SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS PFIZER INC. (US) 1996-12-12 WO disclosed
US-5264204-A Hydrophilic free radicals for magnetic resonance imaging MALLINCKRODT MEDICAL, INC. (US) 1993-11-23 US disclosed
WO-1993022662-A1 HYDROPHILIC FREE RADICALS FOR MAGNETIC RESONANCE IMAGING MALLINCKRODT MEDICAL, INC. (US) 1993-11-11 WO disclosed